Status:
COMPLETED
Anti Infective Agents Impact in COVID-19 Pneumonia
Lead Sponsor:
Centre d'Investigation Clinique et Technologique 805
Conditions:
COVID
Pneumonia, Viral
Eligibility:
All Genders
18+ years
Brief Summary
During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al. proposed the c...
Eligibility Criteria
Inclusion
- aged over 18 years old
- hospitalized for a COVID-19 pneumonia documented by PCR or lung tomodensitometry,
- admitted outside an intensive care unit, in a medicine ward
Exclusion
- patient opposed to data collected, or who could not consent because of a serious presentation of the pneumonia
Key Trial Info
Start Date :
March 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 25 2020
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT04453501
Start Date
March 2 2020
End Date
April 25 2020
Last Update
July 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Benjamin Davido
Garches, France, 92380